Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.16% | 2.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.19% | -13.77% | |||
| Operating Income | -24.19% | 13.77% | |||
| Income Before Tax | -25.81% | 12.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.81% | 12.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.81% | 12.66% | |||
| EBIT | -24.19% | 13.77% | |||
| EBITDA | -24.60% | 14.05% | |||
| EPS Basic | -23.25% | 12.74% | |||
| Normalized Basic EPS | -23.25% | 12.75% | |||
| EPS Diluted | -23.25% | 12.74% | |||
| Normalized Diluted EPS | -23.25% | 12.75% | |||
| Average Basic Shares Outstanding | 2.08% | 0.09% | |||
| Average Diluted Shares Outstanding | 2.08% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||